Analyst Ratings for Coherus Biosciences (CHRS)
CHRS Rating Summary
CHRS Price Target Summary
- Highest: $12.00 (Guggenheim)
- Lowest: $4.00 (Maxim Group)
- Average: $8.25
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$8.25 (+457.4%)
* Over Last 12-Mos
Rating Score: 7.9 / 10
Percentile Rank: 82%
Avg. $ Target:
$8.25 (+457.4%)
* Over Last 12-Mos
Rating Score: 7.9 / 10
Percentile Rank: 82%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/11/2026 | Guggenheim | Paul | New Coverage | Buy (N/A) |
12.00 (N/A) |
1.75 (1.48) |
-15.43% | Details |
| 1/23/2026 | Oppenheimer » Updated 3/10/2026 |
Jay Olson | New Coverage | Outperform (N/A) |
10.00 (N/A) |
1.64 (1.48) |
-9.76% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
